Skip to main content
Marker Therapeutics, Inc. logo

Marker Therapeutics, Inc. — Investor Relations & Filings

Ticker · MRKR ISIN · US57055L1070 US Manufacturing
Open in API
Filings indexed 899 across all filing types
Latest filing 2003-08-14 Interim / Quarterly Rep…
Country US United States of America
Listing US MRKR

About Marker Therapeutics, Inc.

https://markertherapeutics.com/

Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company developing next-generation T cell-based immunotherapies for hematologic malignancies and solid tumors. The company's core technology is its Multi-Antigen Recognizing (MAR) T cell platform, which utilizes natural, non-genetically modified T cells to recognize and kill heterogeneous tumors. This approach is designed to provide durable anti-tumor responses with a favorable safety profile. Its lead product candidate, MT-601, recognizes six tumor-specific antigens and is being evaluated in a Phase 1 study for patients with lymphoma who have relapsed or are ineligible for anti-CD19 CAR-T cell therapy. The technology was originally developed at Baylor College of Medicine.

Recent filings

Filing Released Lang Actions
FORM 10-QSB - JUNE 30, 2003
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-QSB filed with the U.S. Securities and Exchange Commission for the quarterly period ended June 30, 2003. It contains interim consolidated financial statements, including balance sheets, statements of operations, cash flows, and notes to the financial statements. The document explicitly states it is an unaudited interim report prepared in accordance with GAAP and SEC regulations for quarterly reporting. The presence of detailed financial data and management discussion confirms it is a comprehensive quarterly financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2003-08-14 English
S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the U.S. Securities and Exchange Commission. It relates to the registration of securities under the Securities Act of 1933, specifically for a Stock Option Plan of GeneMax Corp. The document includes details about the securities to be registered, indemnification of directors and officers, incorporation by reference of other filings, and legal opinions. It is not a financial report, earnings release, or management discussion, but a registration statement for securities issuance. This type of filing is best classified under Regulatory Filings (RNS) as it is a regulatory compliance document that does not fit into other specific categories like Annual Report or Capital Update.
2003-08-12 English
FORM 10-QSB DATED 03-31-03
Interim / Quarterly Report Classification · 100% confidence The document is a Form 10-QSB filed with the U.S. Securities and Exchange Commission for the quarterly period ended March 31, 2003. It contains detailed interim consolidated financial statements, including balance sheets, statements of operations, cash flows, and notes to the financial statements. The document explicitly states it is an unaudited interim report prepared in accordance with GAAP and SEC regulations for quarterly reporting. The presence of financial data and management discussion confirms it is a comprehensive interim financial report rather than a brief announcement or certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR).
2003-05-15 English
10KSB
Annual Report Classification · 100% confidence The document is titled 'FORM 10-KSB' and is described as an 'ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2002.' It contains detailed sections typical of an annual report, including business description, financial statements, auditor's report, management discussion and analysis, executive compensation, and other comprehensive disclosures. The length of the document (15,000 characters) and the presence of substantive financial data and analysis confirm it is the full annual report rather than an announcement or summary. Therefore, the document fits the definition of an Annual Report (10-K).
2003-04-15 English
NT 10-K
Regulatory Filings Classification · 100% confidence The document is a Form 12b-25 Notification of Late Filing submitted to the U.S. SEC. It specifically states that the company, GeneMax Corp., is notifying the SEC of a delay in filing its Annual Report on Form 10-KSB for the fiscal year ended December 31, 2002. The document explains reasons for the delay and the anticipated filing date. It does not contain the actual annual report or financial statements but is a regulatory notification about the late filing of such a report. According to the classification rules, such a notification is a regulatory filing and not the report itself. Therefore, the appropriate classification is Regulatory Filings (RNS).
2003-04-01 English
5
Director's Dealing
2003-02-14 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.